ICER Atopic Dermatitis Review Prompted By First Biologic
The Institute for Clinical and Economic Review’s assessment of emerging therapies for atopic dermatitis was driven by both excitement and concern from physicians and payers over the anticipated launch of Regeneron/Sanofi’s dupilumab.
You may also be interested in...
The FDA approved the IL-4/IL-13 inhibitor March 28 in a win for Sanofi and Regeneron. The companies set the biologic's price at $37,000 per year, which is lower than many biologics on the market for psoriasis.
Institute for Clinical and Economic Review plans to unveil an updated drug value framework in early 2017.
The pandemic has reignited interest and investment in vaccines across a wide array of disease areas by big pharma and venture investors, a panel of BIO experts said.